X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ALEMBIC LTD - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ALEMBIC LTD ASTRAZENECA PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 125.4 60.2 208.4% View Chart
P/BV x 19.0 3.4 560.8% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
ALEMBIC LTD
Mar-16
ASTRAZENECA PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,28553 2,433.7%   
Low Rs63429 2,163.8%   
Sales per share (Unadj.) Rs189.64.7 4,017.0%  
Earnings per share (Unadj.) Rs-0.28.8 -2.3%  
Cash flow per share (Unadj.) Rs3.89.0 42.7%  
Dividends per share (Unadj.) Rs00.15 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs68.627.7 247.6%  
Shares outstanding (eoy) m25.00267.03 9.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.18.7 58.2%   
Avg P/E ratio x-4,712.74.7 -100,723.1%  
P/CF ratio (eoy) x249.64.6 5,474.1%  
Price / Book Value ratio x14.01.5 944.2%  
Dividend payout %01.7 0.0%   
Avg Mkt Cap Rs m23,98810,962 218.8%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,605238 674.2%   
Avg. sales/employee Rs Th3,040.2NM-  
Avg. wages/employee Rs Th1,029.2NM-  
Avg. net profit/employee Rs Th-3.3NM-  
INCOME DATA
Net Sales Rs m4,7401,260 376.1%  
Other income Rs m92264 34.9%   
Total revenues Rs m4,8321,524 317.0%   
Gross profit Rs m-13083 -156.8%  
Depreciation Rs m10161 164.8%   
Interest Rs m00 0.0%   
Profit before tax Rs m-139285 -48.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m139-32 -431.4%   
Tax Rs m56 83.4%   
Profit after tax Rs m-52,343 -0.2%  
Gross profit margin %-2.76.6 -41.7%  
Effective tax rate %-3.72.1 -171.2%   
Net profit margin %-0.1185.9 -0.1%  
BALANCE SHEET DATA
Current assets Rs m2,7261,689 161.4%   
Current liabilities Rs m2,435486 500.8%   
Net working cap to sales %6.195.4 6.4%  
Current ratio x1.13.5 32.2%  
Inventory Days Days74217 34.0%  
Debtors Days Days4181 50.3%  
Net fixed assets Rs m1,0351,624 63.7%   
Share capital Rs m50534 9.4%   
"Free" reserves Rs m9425,960 15.8%   
Net worth Rs m1,7167,404 23.2%   
Long term debt Rs m0104 0.0%   
Total assets Rs m4,1568,010 51.9%  
Interest coverage xNM950.7-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.2 724.9%   
Return on assets %-0.129.3 -0.4%  
Return on equity %-0.331.6 -0.9%  
Return on capital %031.3 0.0%  
Exports to sales %5.72.9 193.7%   
Imports to sales %6.528.9 22.4%   
Exports (fob) Rs m27037 728.3%   
Imports (cif) Rs m306364 84.2%   
Fx inflow Rs m37537 1,009.7%   
Fx outflow Rs m470365 128.8%   
Net fx Rs m-96-328 29.1%   
CASH FLOW
From Operations Rs m-8346 -2.3%  
From Investments Rs m-146-48 306.1%  
From Financial Activity Rs m862-301 -286.4%  
Net Cashflow Rs m709-3 -23,616.7%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 150.0%  
FIIs % 15.7 9.7 161.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.1 34.9%  
Shareholders   12,856 54,701 23.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 15, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS